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Summary We have investigated in detail the effects of buthionine sulfoximine (BSO), a selective glutathione
(GSH) depleting agent, on the GSH contents of a number of normal tissues and three experimental tumours
in mice. Significant variations in the rate and degree of GSH depletion and recovery were observed among
the normal tissues. Following a dose of 2.5mmolkg-1 BSO, GSH nadirs were reached by approximately 5 h
for the liver and kidney, 8 h for the lung and bone marrow, 12h for red blood cells (RBCs) and by 24h for
the heart. The degree of depletion was greatest for the kidney (80%), liver (74%) and bone marrow (83%),
intermediate for the heart (54%) and lung (40%), and least for RBCs (13%). Recovery of GSH content was
fastest for the liver followed in descending order by the kidney, the lung, the bone marrow, RBCs and the
heart. In contrast, the rate and extent of GSH depletion and recovery showed considerably less variation
among the 3 murine tumours. In the tumours GSH nadirs were reached by 10-12h. The extent of depletion
was about 55-65%. Recovery of GSH levels in the tumours required 48h or more, a longer period than
required by the liver, kidney and lung but shorter than that needed for the bone marrow, heart and RBCs.
Attempts to preferentially deplete tumour GSH by exploiting the differences in recovery rates between normal
tissues and tumours were only partially successful. Multiple BSO dosing at 16h intervals allowed the liver to
recover between doses, but the recovery in the kidney, lung and bone marrow was only partial and no
recovery was seen in the heart. Finally, dose-depletion relationship investigations showed that, with the
exception of the lungs, GSH depletion could be achieved in tumours with doses of BSO lower than those
required for normal tissues.
It is now widely accepted that glutathione (GSH) plays an Materials and methods
important role in the cellular defence against cytotoxic insults.
Some tumour cells cultured in vitro, in particular those of Mice and tumours
human origin, were recently shown to contain extremely high
levels ofGSH (Biaglow et al., 1983; Mitchell et al., 1985). The All experiments were performed on 8-12 week-old inbred,
possible relevance of GSH in cancer chemotherapy and the female C3H/HeJ mice (Jackson Lab., Bar Harbor, ME). The
development of resistance during the course of treatment was murine sarcoma KHT (Kallman et at., 1967) and RIF-1
emphasized by the findings that tumour cells made resistant (Twentyman et al., 1980), and the mammary carcinoma 1i6C
to some anti-cancer drugs, e.g. melphalan, cis-platin and (Corbett et at., 1978) were grown in the gastrocnemius
adriamycin, have increased cellular GSH concentrations muscle. Tumour-bearing mice were given BSO when tumours
(Suzukake et al., 1982; Green et al., 1984; Hamilton et al., were between 250-350mg.
1985). For these reasons much current interest has focused
on techniques of reducing cellular levels of GSH prior to Drug administration
treatment with cytotoxic agents. The development of Buthionine sulfoximine (BSO), obtained in mixed
buthionine sulfoximine (BSO), a specific inhibitor of GSH enantiomeric form (DL-buthionine-SR-sulfoximine) from
synthesis, has removed much of the uncertainties due to Sigma Chemical Co., was dissolved in phosphate buffer
unwanted side-effects that were associated with GSH solution, pH 7.4, and injected i.p. at 0.01-0.04mlg-1 of
depleting agents having less specificity. Recent in vitro mice.
studies using human tumour cell lines have shown that
depletion of cellular GSH by BSO can indeed increase the Sample preparation
cytotoxicity of a variety of anti-cancer drugs (Green et al.,
1984; Hamilton et al., 1985; Crook et al., 1986; Lee et al., Mice were sacrificed at various times following BSO
1986). treatment by cervical dislocation. Organs and tumours were
Because of these promising developments, BSO in then removed, rapidly washed in 10mm 5-sulfosalicyclic
conjunction with chemotherapeutic drugs is likely to enter acid/EDTA (5mM) (Sigma), and dried on tissue paper. These
clinical trial in the near future. However, it is as yet not were then frozen immediately by immersing in liquid
clear whether a therapeutic benefit can be obtained by nitrogen and stored at -70°C until analysis. To obtain bone
selectively depleting tumour GSH contents while partly or marrow cells, femurs were removed, cleared from
wholly sparing the critical normal tissues. Consequently surrounding muscle, and washed with cold saline. Marrow
additional information on the in vivo use of BSO would was then expressed by flushing through with 1.0ml cold
greatly assist the planning of such clinical trials. Critical to saline using a needle and syringe. Marrows from the same
such studies is a detailed knowledge of the GSH depletion group were pooled and syringed repeatedly to obtain a single
kinetics of normal tissues compared to tumours. cell suspension. The suspension then was diluted
Furthermore, since the dose-limiting normal tissues may appropriately and nucleated cells were counted using a
differ from drug to drug, information on a wide spectrum of Coulter Counter/Channelyzer following lysis of RBCs with
critical normal tissues is clearly needed. In this study, we Zapoglobin II (Coulter). Aliquots of the original suspension
have investigated in detail the dose-response relationships were diluted with excess 3% glacial acetic acid to lyse
and kinetics of GSH depletion by BSO in a range of normal unnucleated cells and were then centrifuged at lO00g for
tissues and tumours in mice. 10mmn. The resultant pellet was stored at -70°C until
analysis.
Correspondence: F.Y.F. Lee. Tissues were homogenized with 20vol (w/v) of 20mM 5-
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homogenized with 200PI SSA. Tissue or cell homogenates Table I The initial and nadir GSH concentrations in a range of
were centrifuged for 40 sec in an Eppendorf microcentrifuge. normal tissues and 3 murine tumour models obtained from
GSH in the SSA supernatant was derivatized using the untreated mice and from mice treated with a single dose of
fluorescent reagent monobromobimane (3-(bromoethyl)-2,5,6- 2.5mmolkg-1 BSO respectively. Data were calculated from 3
trimethyl-lH, 7H-pyrazolo [1,2-a] pyrazole-1,7-dione; mBBR, individual experimenets; 20-30 mice were used in each experiment
Calbiochem., LaJolla, CA). Aliquots (180,l) of the GSH levels in GSH nadir concentrations
supernatant were pipetted into glass tubes containing 12PI of Tissuel untreated mice after a single dose ofBSO
N-ethylmorpholine (0.5 M in 20mM KOH) and 2 p1 of tumour (fmolcellU or mmolkg 1)a (fmolcell-I or mmolkg 1)a
mBBR (50mM in acetonitrile) and the sample immediately
vortexed and stored in the dark at 4°C before analysis. Liver 8.0+0.68b 2.08+0.34b (26)C
Kidney 2.83+0.33 0.567+0.06 (20)
HPLC Bone
marrow 0.3+0.05 0.05 +0.01 (17)
The isocratic HPLC technique used for the analysis of GSH Lung 1.20+0.02 0.72+0.11 (60)
was modified from the method of Minchinton (1984) and Heart 1.11+0.07 0.511+0.09 (46)
has been described previously (Lee et al., 1986). Briefly, RBCs 0.142+0.021 0.124+0.0i5 (87)
separation of GSH was carried out on Waters Radial-PAK KHT 2.63+0.16 0.870+0.16 (33)
reversed-phase bonded octadecylsilane cartridge columns RIF-1 2.03+0.22 0.832+0.21 (41)
(8mm I.D., 5,um diameter spherical particles). The mobile 16C 1.26+0.09 0.529+0.09 (42)
phase consisted of 23% acetonitrile in 40mM ammonium
phosphate, pH 7.2, containing 5mM tetra-butyl-ammonium aThe units were fmolcell-o for bone marrow and RBCs and
hydroxide, The effluent was monitored for fluorescence with
340nm excitation and emission at >410nm. The coefficients
percent of untreated controls is given in parentheses.
of variation were 7.1% and 6.4% at GSH concentrations of
0.5mM and 5mM respectively.
The time course ofGSH depletion by single dose BSO
Results Following a single dose of 2.5mmolkg-1 BSO, the GSH contents of the various normal tissues were depleted in a
time-dependent manner (Figure 1). Kidney and liver showed GSH concentrations in various normal tissues and three murmne tiedpnntm nr(Fge1)Kdeyadlvrsod tuHmours
ntrations in various normal tissues and three murine the most rapid rates of depletion, with GSH levels reaching tumours nadirs by -5 h. Intermediate rates of depletion were seen in
The GSH contents of the normal tissues and tumours the lung and bone marrow with nadirs at 4-16h and 8-12h
studied are listed on Table I. Among the normal tissues the respectively. The heart was depleted the most slowly with a
liver was found to have the highest GSH concentration nadir in GSH at 24-72h. The extent of GSH depletion
followed, in descending order, by the kidney, the lung, and following a single dose of BSO also differed significantly
the heart. Among the three murine tumours studied the between tissues (Figure 1; Table I). The most severe
KHT and RIF-1 sarcomas had similar GSH contents, depletion occurred in the liver, kidney and bone marrow; the
whereas the 16C mammary carcinoma had significantly less heart and the lung showed intermediate depletion, and RBCs
GSH (Table I). showed the least depletion. The recovery rates of GSH in the
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Figure 1 GSH contents as percent of initial concentrations in various normal tissues following a dose of 2.5mmolkg-1 BSO.
Each datum point represents the average of 3 mice. Data are from 3 independent experiments. The initial GSH concentration for
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and tumours was monitored at the time of the GSH nadir.
100 Figure 3 shows the data for the normal tissues and Figure 4
- 1_ - - - 5) those for the tumours. Great variations were observed
between normal tissues in terms of sensitivity to BSO but
o | , I 0 little difference was seen in the three tumours. The maximum
o depletion that could be achieved with a single dose of BSO
was again different for the various normal tissues, but
o similar for the tumours (Figures 3 and 4). BSO was least
effective at depleting RBCs of GSH, intermediately effective
L; 50 - '¢ . / ,' .for the heart and the lung and the most efficacious for the
A RIF-1 liver, kidney and bone marrow.
0 KHT
A 16C GSH depletion by multiple doses ofBSO
To attempt to exploit further the differences in the recovery
kinetics between some critical normal tissues and tumours,
C L2 BSO was given every 16h to mice bearing 16C tumours. At o 16 32 48 this time GSH concentrations were at the nadir for tumours
Time (hours) whereas in some normal tissues recoveries had already begun
Figure 2 GSH contents as percent of initial concentration in 3 (Figures 1 and 2). Figure 5 shows the effects of giving 3
murine tumour models following a dose of 2.5mmolkg-1 BSO. doses of BSO at 16h intervals on the GSH contents of
Each datum point is the average of 3 tumours; error bars various normal tissues and 16C tumours. With this
indicate +1 s.d. Data are from 2 independent experiments. The treatment regimen, tumour GSH levels were depleted to 25%
initial GSH concentration for each tumour is given in Table I. of untreated control values after 3 doses of BSO. The most
rapidly recovering organ, the liver, recovered fully 16h after
various tissues following a single dose of BSO also differed the third dose. The lung, kidney and bone marrow recovered
considerably (Figure 1). Recovery, to pretreatment values, more slowly reaching 58, 46 and 38% of control by this
was most rapid for the liver (16h) followed by the kidney time. The heart, however, showed no recovery, and was
(30h), the lung (32h), and bone marrow (72h). Recovery down to 20% of control GSH concentration. Finally, 16C
was extremely slow for the heart (>96h) and RBCs (>72h). tumours also showed little recovery with GSH
Furthermore, for the lung and in particular the liver and concentrations reduced to 30% of control at this time.
kidneys a pronounced 'overshoot' in GSH levels occurred
during recovery, i.e. GSH concentrations rose significantly
above those for untreated controls.
Unlike the considerable variation seen in normal tissues Discussion
(Figure 1) the rate and extent of GSH depletion in the 3
murine tumours following a single dose of BSO The present results demonstrate considerable diversity in the
(2.5 mmol kg-1) were similar (Figure 2 and Table I) response of the various normal tissues and tumours to
Recoveries, however, were more rapid in the KUT and RIF treatment with the specific GSH depleting agent BSO.
1 tumours than in the16wC mammary carcinoma (Figure 2). Although investigations of the use of BSO as a tool in I
probing GSH metabolism and function, especially in cellular
The dose-response relationship ofGSH depletion by BSO defense mechanism have been numerous, the details of GSH depletion and recovery kinetics following BSO treatment as
The BSO dose-response relationship for all normal tissues well as the important question of dose selection in vivo have
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Figure 3 The dose-response relationship between BSO and GSH depletion in various normal tissues in mice. GSH contents are
expressed as percent of initial concentration. Each datum point represents the average of 3 mice; error bars indicate+ 1 s.d. Data
are from 2 independent experiments.36 F.Y.F. LEE et al.
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Figure 4 The dose-response relationship between BSO and GSH depletion in 3 murine tumour models. GSH contents are
expressed as percent of initial concentration. Each datum point represents the average of 3 mice; error bars indicate + 1 s.d. Data
are from 3 independent experiments.
150 - concentration following depletion, or (ii) the percent
2.5mml g1BS depletion of the initial GSH content which is the important
$ ffi 9 parameter governing the chemo- and radiosensitization
9 ,^ effects of GSH depletion. Since different tissues have vastly
- /, ,#, different steady state GSH levels, the effects of GSH
Liver
depletion indicated by these parameters differ
dramatically. For example, the GSH content of the liver
+" 100 . ., g . o Ifollowing depletion to 25% of its initial level is still greater
o j than that of the untreated lung. In addition, a related
0 o t Q! . . , ~~~~~~~~~questioncentral to this debate is whether the various tissues
-P have different GSH content for reasons of biological
/ i 1F>\, , : ,' \ ', , necessity or whether some tissues simply have large reserves
o C\ -h°,> '^ ,' ', , Lof GSH that are not normally needed. The fact that tumour
Lung responses to some cytotoxic agents could be enhanced
n50 through GSH depletion whereas the cytotoxicity to the lung
/ / A->\,* ,\\ .5 Bone and bone marrow, two tissues with lower initial GSH
"";'/ / > Al i->_ , Marrow content, were unaffected (see later), perhaps suggest a large ,e / /t > : ^ 16C degree of tissue dependence. If this were the case then the
- ' ^ iS \ Heart percent depletion for a particular tissue might be a more
important factor. For this reason the percent depletion
parameter primarily was used in the following discussion.
°0 16 32 48 Where necessary the absolute GSH levels can be deduced
Time (hours) from the values of initial GSH content given in Table I.
Figure 5 The effects of multiple BSO-dosing at 16h intervals on In agreement with previous reports (Griffith and Meister,
the GSH contents of various normal tissues and the 16C 1979; Moron et al., 1979; Hazelton and Lang, 1980), the
mammary carcinoma. Arrows indicate the time at which BSO GSH contents were found to differ widely among different
was administered. Data are from 2 independent experiments. normal tissues in the mouse. The highest concentration,
found in the liver, was approximately 7 times that observed
in the lung and the heart (Table I). Further the bone marrow
not yet been fully examined. A major aim of the present has very low GSH content. Much less variation was seen in
study was to attempt to delineate dosing and timing the 3 murine tumour models studied. The GSH contents in
protocols which might result in differential depletion of the tumours were relatively high in comparison with most
tumour GSH content. In this respect, the data presented normal tissues except for the liver and kidney (Table I;
revealed clear differences between normal tissues and Griffith & Meister, 1979). Even higher GSH concentrations
tumours which may be exploitable in the design of treatment have been observed in human tumour xenografts grown in
regimens. nude mice (Allalunis-Turner et al., unpublished results).
The ultimate goal in the manipulation of GSH levels is to Because of accumulating evidence implicating GSH in the
improve the therapeutic index of a treatment regimen. cellular defence against anticancer agents (for review see
However, a rational treatment strategy design will not be Arrick & Nathan, 1984), much effort has been focused on
possible unless the relationship between the critical reducing cellular GSH contents prior to treatment. BSO, a
parameters of GSH depletion and the resultant biological selective inhibitor of the GSH synthesis enzyme y-glutamyl
effects are known. It is, for example, a matter of much cysteine synthetase is considered superior to other depleting
current debate as to whether it is (i) the absolute GSH agents because of its specificity and lack of side-effects.GLUTATHIONE DEPLETION BY BUTHIONINE SULFOXIMINE 37
However, with a single high dose of BSO (2.5mmolkg-1),
selective depletion of tumour GSH cannot be achieved
(Figure 1 vs. Figure 2). Following such treatment, depletion
was greater in the liver, kidney and bone marrow than in all
3 tumour systems studied (Table I). This is in agreement
with the results of Minichinton and coworkers (1984) who
observed patterns of GSH depletion in the liver and kidney
as well as in tumours very similar to those reported here. In
addition, attempts at preferential tumour depletion through
multiple BSO exposures showed that selection through
differential recovery rates was not entirely successful (Figure
5). In these multiple-dosing experiments GSH recovery in the
liver was complete but recoveries in the lung, kidney and
bone marrow were only partial. Furthermore, although with
this treatment regimen, the GSH concentration of the 16C
tumour could be severely reduced to 25% of pretreatment
level, a similar reduction to 20% of initial concentration also
was observed in the heart. This result was not unexpected
because of extremely slow GSH recovery kinetics in this
normal tissue (Figure 1). Since the heart is the dose-limiting
tissue for the cytotoxic agent adriamycin (Lefrak et al.,
1973), caution should be exercised in any clinical trial
considering the combination of adriamycin plus BSO so that
cardiotoxicity is not enhanced through severe GSH
depletion.
In contrast to the GSH kinetics investigations, the dose-
response data (Figures 3 and 4) showed differences in GSH
depletion between tumour and normal tissues which might
be exploited to minimize adverse depletion in normal tissues,
in particular the heart (Figures 3 and 4). The GSH content
in the three tumour systems could be depleted considerably
using lower doses of BSO than all normal tissues except the
lungs. However, it remains to be seen whether such
depletions are sufficient to enhance the tumoricidal effects of
chemotherapeutic agents. If this were the case it may be
possible to avoid or minimize GSH depletion in normal
tissues by giving smaller doses of BSO. It should be noted
that this approach will not be successful for the lung because
of its greater sensitivity to BSO. However, by using multiple
low dose schedules to take advantage of the faster recovery
kinetics of the lung, coupled with the fact that depletion in
the lung is less severe than in other tissues, adverse effects in
the lung also may be avoided. Experiments to exploit this
possibility are currently in progress.
The ability of BSO to potentiate the antitumour activity of
chemotherapeutic agents has been demonstrated convincingly
in vitro in human tumour lines for adriamycin (Hamilton et
al., 1985; Lee et al., 1986), melphalan (Hamilton et al., 1985;
Green et al., 1984), cis-platinum (Hamilton et al., 1985; Lee
et al., unpublished) and activated cyclophosphamide (Lee et
al., unpublished results). In vivo chemosensitization also has
been reported for cyclophosphamide (Ono & Shrieve, 1986;
Tsutsui et al., 1986), bleomycin (Tsutsui et al., 1986), cis-
platin (Tsutsui et al., 1986), adriamycin (Lee & Siemann, in
preparation) and melphalan (Alliet & Siemann, in
preparation). However, ultimately the important question to
be addressed is whether a therapeutic benefit can be achieved
with combined cytotoxic agent-BSO treatment. While the
data are limited, several studies have indicated that
combining BSO with cytotoxic agents did not adversely
affect normal tissue toxicity. For example, Russo and
coworkers (1986) showed no effect of BSO on CFU-S
survival and peripheral WBC counts following melphalan
treatment. A similar result was found in our laboratory
(Alliet and Siemann, in preparation). In Addition we have
observed that a 2.5mmolkg-I dose of BSO had no effect on
the acute lethality of adriamycin (Lee & Siemann, in
preparation) and no detectable effect on the lung toxicity of
cyclophosphamide as measured by breathing rate or lung
lavage protein assays (Allalunis-Turner et al., unpublished
results). Evidence so far is thus supportive of the idea that
the therapeutic index of some chemotherapeutic drugs may
be improved by BSO. It must be emphasized, however, that
much more in-depth studies using normal tissue toxicity
models best suited for each particular cytotoxic drug should
be carried out before combination therapy with BSO can
safely be used in patients.
Finally, if BSO is to be used in patients, the important
question which needs to be addressed is how to monitor
GSH depletion. The present results clearly indicate that no
single normal tissue is representative of all others. The best
strategy may be to monitor the GSH content of the critical
dose-limiting tissue. As this is clearly not practical for all
tissues, an alternative may be to monitor two or more tissues
with different GSH response profiles, such as RBCs and
bone marrow.
In conclusion, the present results indicate that the optimal
use of BSO with chemotherapeutic drugs requires the
detailed knowledge of the GSH kinetics in normal tissues
and in tumours. For some normal tissues consideration
probably will need to be given to both dose-timing and dose-
selection in order to avoid severe GSH depletion.
This work was supported by NIH grants CA-36858, CA-O 1051, CA-
38637 and CA-44127. MJAT was the recipient of a fellowship from
the Alberta Heritage Foundation for Medical Research. The authors
thank B. Granger for preparation of the manuscript.
References
ARRICK, B.A. & NATHAN, C.F. (1984). Glutathione metabolism as a
determinant of therapeutic efficacy: A review. Cancer Res., 44,
4224.
BIAGLOW, J.E., CLARK, E.P., EPP, E.R., MORSE-GUARDIO, M.,
VARNES, M.E. & MITCHELL, J.B. (1983). Non-protein thiols and
the radiation response of A549 human lung carcinoma cells. Int.
J. Radiat. Biol., 44, 489.
CORBETT, T.M., GRISWOLD, JR, D.P., ROBERTS, B.J., PECKHAM,
J.C. & SCHABEL JR., F.M. (1978). Biology and therapeutic
response of a mouse mammary adenocarcinoma (16/c) and its
potential as a model for surgical adjuvant chemotherapy. Cancer
Treat. Rep., 62, 1471.
CROOK, T.R., SOUHAMI, R.L., WHYMAN, G.D. & McLEAN, A.E.M.
(1986). Glutathione depletion as a determinant of sensitivity of
human leukemia cells to cyclophosphamide. Cancer Res., 46,
5035.
GREEN, J.A., VISTICA, D.T., YOUNG, R.C., HAMILTON, T.C.,
ROGAN, A.M. & OZOLS, R.F. (1984). Potentiation of melphalan
cytotoxicity in human ovarian cancer cell lines by glutathione
depletion. Cancer Res., 44, 5427.
GRIFFITH, O.W. & MEISTER, A. (1979). Glutathione: Interorgan
translocation, turnover, and metabolism. Proc. Natl Acad. Sci.,
76, 5606.
HAMILTON, T.C., WINKER, M.A., LOWE, K.G. & 7 others (1985).
Augmentation of adriamycin, melphalan, and cisplatin
cytotoxicity in drug-resistant and -sensitive human ovarian
carcinoma cell lines by buthionine sulfoximine mediated
glutathione depletion. Biochem. Pharmacol., 34, 2583.
HAZELTON, G.A. & LANG, C.A. (1980). Glutathione contents of
tissues in the aging mouse. Biochem. J., 188, 25.
KALLMAN, R.F., SILINI, G. & VAN PUTTEN, L.M. (1967). Factors
influencing the quantitative estimation of the in vivo survival of
cells from solid tumors. J. Natl Cancer Inst., 39, 539.
LEE, F.Y.F., VESSEY, A.R. & SIEMANN, D.W. (1986). Glutathione as
a determinant of cellular response to adriamycin. NCI
monograph (in press).
LEFRAK, E.A., PITHA, J., ROSENHEIM, S. & GOTTLIEB, J.A. (1973).
A clinicopathologic analysis of adriamycin cardiotoxicity.
Cancer, 32, 302.
MINCHINTON, A.l. (1984). Measurement of glutathione and other
thiols in cells and tissues: A simplified procedure based on the
HPLC separation of monobromobimane derivatives of thiols.
Int. J. Radiat. Oncol. Biol. Phys., 10, 1503.38 F.Y.F. LEE el al.
MINCHINTON, A.I., ROJAS, A., SMITH, K.A. & 4 others (1984).
Glutathione depletion in tissues after administration of
buthionine sulfoximine. Int. J. Radial. Oncol. Biol. PhVs., 10,
1261.
MITCHELL, J.B., MORSTYN, G., RUSSO, A. & CARNEY, D.N. (1985).
In vitro radiobiology of human lung cancer. Cancer Treat.
Symposia, 2, 3.
MORON, M.A., DEPIERRE, J.W., MANNEVIK, B. (1979). Levels of
glutathione, glutathione reductase and glutathione S-transferase
activities in rat lung and liver. Biochim Biophys. Acta, 582, 67.
ONO, K. & SHRIEVE, D.C. (1986). Enhancement of EMT6/SF tumor
cell killing by mitomycin C and cyclophosphamide following in
vivo administration of buthionine sulfoximine. Int. J. Radiat.
Oncol. Biol. Phys., 12, 1175.
RUSSO, A., TOCHNER, Z., PHILLIPS, T. & 5 others (1986). In vivo
modulation of glutathione by buthionine sulfoximine: Effect on
marrow response to melphalan. Int. J. Radiat. Oneol. Biol. Phys.,
12, 1187.